Despite this recent breakthrough in the treatment of patients with advanced HCC, there remains an unmet need for reliable biomarkers of response to immunotherapy.GH level have been reported and validated as a prognostic marker in HCC patients [7, 12, 13]. Here, GH1 is linked to hepatocellular carcinoma.